![Author ORCID: We display the ORCID iD icon alongside authors names on our website to acknowledge that the ORCiD has been authenticated when entered by the user. To view the users ORCiD record click the icon. [opens in a new tab]](https://chemrxiv.org/engage/assets/public/chemrxiv/images/logos/orcid.png)
Abstract
We report a new synthesis of the Covid-19 drug nirmatrelvir featuring a highly enantioselective biocatalytic desymmetrization and a diastereoselective multicomponent reaction as the key steps. Our route avoids the use of transition metals and peptide coupling reagents, resulting in an overall highly atom-economic process.
Content
Supplementary material
Chemoenzymatic Multicomponent Synthesis of Nirmatrelvir
We report a new synthesis of the Covid-19 drug nirmatrelvir featuring a highly enantioselective biocatalytic desymmetrization and a diastereoselective multicomponent reaction as the key steps. Our route avoids the use of transition metals and peptide coupling reagents, resulting in an overall highly atom-economic process.We report a new synthesis of the Covid-19 drug nirmatrelvir featuring a highly enantioselective biocatalytic desymmetrization and a diastereoselective multicomponent reaction as the key steps. Our route avoids the use of transition metals and peptide coupling reagents, resulting in an overall highly atom-economic process.
